A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Status:
RECRUITING
Trial end date:
2030-08-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
Phase:
PHASE1
Details
Lead Sponsor:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company